Generate Investment Management Ltd Acquires 69,423 Shares of Novo Nordisk A/S $NVO

Generate Investment Management Ltd grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 43.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 229,962 shares of the company’s stock after acquiring an additional 69,423 shares during the period. Generate Investment Management Ltd’s holdings in Novo Nordisk A/S were worth $12,761,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Revolve Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. Jump Financial LLC bought a new stake in Novo Nordisk A/S during the first quarter worth $340,000. State of Wyoming bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $38,000. Graham Capital Management L.P. bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $1,132,000. Finally, Focus Partners Advisor Solutions LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth $437,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $51.19 on Wednesday. The firm’s 50 day simple moving average is $49.19 and its 200 day simple moving average is $56.21. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $228.55 billion, a PE ratio of 14.88 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non‑injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.
• Positive Sentiment: First‑mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP‑1 market share and trial data show strong weight‑loss results for oral Wegovy, which could help retention vs. competitors. Read More.
• Neutral Sentiment: Macro/ETF flow tailwinds — FDA nod to an oral GLP‑1 is expected to lift healthcare and obesity‑focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.
• Neutral Sentiment: Short‑term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.
• Negative Sentiment: Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.
• Negative Sentiment: Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.
• Negative Sentiment: Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.